

# The ACT-Accelerator

## Sharpened Priorities & Financing Needs

Member States COVID-19 Briefing

5 November 2020

# Access to COVID-19 Tools Accelerator (ACT-A)


## 2 over-riding objectives

- accelerate the development of new diagnostics, treatments & vaccines
- achieve equitable global access to *all* COVID-19 tools

# 10 months into the pandemic, >46 M people have already been infected & 1.2 M people have died


Northern hemisphere enters flu season already suffering 2<sup>nd</sup> wave.

- rate of new cases doubled in Oct, reaching 500,000/day
- Europe enters 2<sup>nd</sup> lockdown



# 2 months ago, ACT-Accelerator moved into scale-up

Scale-up Plan & Investment Case, Released 25 September 2020



**Status Report & Plan** provides an overview of ACT-Accelerator's goal, approach, achievements to date & near-term priorities. [Link](#)

**Investment Case** provides an economic rationale for investing in ACT-A as a global, integrated, 'end-to-end' solution. [Link](#)



# ACT-A has already **hit key landmarks in its scale-up phase**

(examples at 4 Nov 2020)



**new Rapid Tests** approved, with volume & price guarantees for LICs/LMICs (120m tests @ \$3-5/unit over 6 months)



**1<sup>st</sup> life-saving therapy** in rollout (Dexamethasone) with 3 M doses for LICs; **monoclonal antibodies** in evaluation for LICs




**COVAX Facility 'in business' with 186+** economies (>90% of world population); dynamic vaccine portfolio



**Equitable Allocation Framework & COVAX Allocation Mechanism** established

# Halfway through ACT-A's scale-up phase, **4 major trends** are driving sharper priorities & updated funding needs



Deeper **understanding of the evolving product portfolio**




**Imminent product 'read-outs'** could impact end of pandemic



Equitable access threatened by **lack of funding & in-country capacities**




New evidence that **multilateralism accelerates global recovery**




# ACT-A is helping to **save lives with these tools & accelerate other game changing products** in the coming months


Increasing disease severity




Pre ACT-A



by November



by March 2021



XXX New tool  ACT Accelerator  
ACCESS TO COVID-19 TOOLS

PPE = Personal Protective Equipment, PCR = Polymerase Chain Reaction, Dexa = Dexamethasone, RDT = Rapid Diagnostic Test, mAbs = Monoclonal Antibodies

# But access to these critical tools differs widely across countries & could worsen without urgent financial & political action



## Prevent

*PPE use*



## Protect

*Vaccine deals*



## Test

*RDT/PCR use*



## Treat

*Dexa use*

*High Income*



*Low income*



Access level of tools

■ ■ ■ ■ Rare    ■ ■ ■ ■ Common

PPE = Personal Protective Equipment, PCR = Polymerase Chain Reaction, Dexa = Dexamethasone, RDT = Rapid Diagnostic Test, mAbs = Monoclonal Antibodies



# ACT-A aims to **start changing the fundamental dynamic of the pandemic by March**



## **Diagnostics**

**Expanded testing globally:** with immediate increase in the number & volume of high-quality RDTs and facilitating their use



## **Therapeutics**

**Wider availability of treatments to save lives:** by accelerated use of Dexamethasone & oxygen and secured production capacities for mAbs



## **Vaccines**

**Full vaccination readiness:** with doses secured for global rollout to +20% of population; further R&D, tech transfer & capacity scale-out




## **Health systems connector**

**Best practice for delivering COVID-19 tools established and in roll out:** with rapid assessments, integrated delivery plans, large scale PPE use and key systems investments

# US\$4.5 B is required urgently for this near-term ACT Accelerator scale-up and impact

**Evolution of ACT-A funding need –\$US B**



**Urgent ACT-A financing gap per Pillar –\$US B**

Pillar	Gap (US\$ B)
Diagnostics	1.1
Therapeutics	0.75
Vaccines	1.0
HS Connector	1.7
<b>TOTAL</b>	<b>4.5</b>

1. incl. US\$ 0.1 B by Gavi for Vaccine Procurement/Delivery; 2. COVAX Facility manufacturing & procurement costs financed by self-financing participants (SFP) [List of SFPs](#)

"...if medical solutions can be made available faster and more widely relative to our baseline, it could lead to a cumulative increase in global income of almost \$9 trillion by end-2025"

*IMF World Economic Outlook, October 2020*

Addressing ACT-A's urgent needs = only **1 day** of that income and would save countless lives

# On 2 November, **the ACT-A Facilitation Council** discussed the evolving priorities & urgent financing needs

## Programme Summary

**Co-Chairs:** MoH, South Africa & Min Int'l Dev, Norway

**Participation:** 165 delegates & invitees online

### **Session I – Access to ACT-A's New & Emerging Tools**

- Keynote: Sir Witty, WHO Special Envoy
- Panel: Dr Nsanzimana (Rwanda), Sir Farrar (Wellcome)
- Speakers: St Kitts & Nevis, Singapore, Japan, China, Republic of Korea, Russia, Vietnam, Spain, Saudi Arabia

### **Session II – Urgent Macroeconomic Case for ACT -A**

- Keynote: Lord Jim O'Neill & Petya Koeva (IMF)
- Panel: Ms Murthi (World Bank), J Denton (ICC), CSO
- Speakers: Canada, India, Brazil, CSO

### **Closing Call to Action**

- France & Saudi Arabia (Paris Peace Forum & G20)
- UK & Italy (incoming G7 & G20)

## Some Highlights

*'Midway into the scale-up phase, ACT-A's promise of equitable access is under threat due to serious financing gaps...'*

**Minister Ulstein, Norway**

*'Every country will need to play a part in financing an end to this crisis. Every leader has political choices to make.'*

**Minister Mkhize, South Africa**

*'The time for talking is over. There is an exit strategy through WHO & ACT-A.'*

**Jeremy Farrar, Wellcome**

*'ACT-A needs < 1/10 of 1% of global GDP; this is the easiest decision for world leaders.'*

**Lord Jim O'Neill**

# Next Steps

- Incorporate final comments and publish *ACT-A Urgent Priorities & Financing Gaps (at 9 Nov 2020)*
- Finalize and issue the *ACT-A Facilitation Council Co-Chairs Summary & Next Steps*
- Intensify the ACT-A Advocacy Campaign, particularly through Paris Peace Forum (11-13 Nov) & G20 Leaders Summit (21-22 Nov)

